Also: Nvidia earnings on deck, potential stock splits and big gains, a look at gold, and the Moneyist pulls no punches.
Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果